References
- World Health Organization. WHO Coronavirus (COVID-19) dashboard 2023 [Mar 27, 2023]. Available from: https://covid19.who.int/table
- World Health Organization. Urgent action needed to tackle stalled progress on health-related sustainable development goals 2023 [updated May 19, 2023 ; June 9, 2023]. Available from: https://www.who.int/news/item/19-05-2023-urgent-action-needed-to-tackle-stalled-progress-on-health-related-sustainable-development-goals
- Ministry of Health Malaysia. The latest data on the pandemic in Malaysia 2023 [updated 31 May 2023]. Available from: https://data.moh.gov.my/covid
- Jayaraj VJ, Ng CW, Bulgiba A, et al. Estimating the infection burden of COVID-19 in Malaysia. PLoS Negl Trop Dis. 2022 Nov;16(11):e0010887. doi: 10.1371/journal.pntd.0010887
- Hamdan NEA, Fahrni ML, Lazzarino AI. COVID-19 vaccination prioritization strategies in Malaysia: a retrospective analysis of early evidence. Vaccines. 2023;11(1):48. doi: 10.3390/vaccines11010048
- Star T Covid-19: MOH targets to have 50% of children vaccinated before start of school session, says KJ 2022 [updated 13 Mar 2022;2 June 2022]. Available from: https://www.thestar.com.my/news/nation/2022/03/13/covid-19-moh-targets-to-have-50-of-children-vaccinated-before-start-of-school-session-says-kj
- Ministry of Health Malaysia.COVIDNOW in Malaysia 2023 [updated 6 Oct 2022]. Available from: https://covidnow.moh.gov.my/
- Johns Hopkins University and Medicine. Coronavirus Resource Center 2023 [updated 10 Mar 2023;27 March 2023]. Available from: https://coronavirus.jhu.edu/region/malaysia
- World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant 2022 [updated 21 Jan 2022;19 July 2023]. Available from: https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states
- Wong MTJ, Dhaliwal SS, Balakrishnan V, et al. Effectiveness of booster vaccinations on the control of COVID-19 during the spread of omicron variant in Malaysia. Int J Environ Res Public Health. 2023 Jan 16;20(2):1647. doi: 10.3390/ijerph20021647
- UK Health Security Agency. COVID-19 vaccine surveillance report: week 24. 2022.
- Tartof SY, Slezak JM, Puzniak L, et al. Durability of BNT162b2 vaccine against hospital and emergency department admissions due to the omicron and delta variants in a large health system in the USA: a test-negative case–control study. Lancet Respir Med. 2022;10(7):689–699. doi: 10.1016/S2213-2600(22)00101-1
- Tartof SY, Slezak JM, Puzniak L, et al. Immunocompromise and durability of BNT162b2 vaccine against severe outcomes due to omicron and delta variants. Lancet Respir Med. 2022;10(7):e61–e62. doi: 10.1016/S2213-2600(22)00170-9
- Rosenblum HG, Wallace M, Godfrey M, et al. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines—United States. Morbidity Mortality Weekly Rep. 2022 Oct;71(45):1436–1441. doi: 10.15585/mmwr.mm7145a2
- Tham L Explained: the Covid-19 bivalent vaccine 2023 [updated 13 Jan 2023]. Available from: https://www.freemalaysiatoday.com/category/nation/2023/01/13/explained-the-covid-19-bivalent-vaccine/
- Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the Pfizer-BioNTech COVID-19 vaccine (Bnt162b2) in the first year of rollout in the United States. J Med Econ. 2022;25(1):605–617. doi: 10.1080/13696998.2022.2071427
- Cooper I, Mondal A, Antonopoulos CG. A SIR model assumption for the spread of COVID-19 in different communities. Chaos, Solitons & Fractals. 2020 Oct;139:110057. doi: 10.1016/j.chaos.2020.110057
- Amaro JE, Dudouet J, Orce JN. Global analysis of the COVID-19 pandemic using simple epidemiological models. Appl Math Modell. 2021;90:995–1008. doi: 10.1016/j.apm.2020.10.019
- Calafiore GC, Novara C, Possieri C. A time-varying SIRD model for the COVID-19 contagion in Italy. Annu Rev Control. 2020;50:361–372. doi: 10.1016/j.arcontrol.2020.10.005
- Ndaïrou F, Area I, Nieto JJ, et al. Mathematical modeling of COVID-19 transmission dynamics with a case study of Wuhan. Chaos, Solitons & Fractals. 2020;135:109846. doi: 10.1016/j.chaos.2020.109846
- Ministry of Health Malaysia. Pharmacoeconomic guidelines for Malaysia. Second ed. Selangor, Malaysia: Ministry of Health Malaysia. 2019.
- Department of Statistics Malaysia. Population by age group, sex and ethnic group, 2010 – 2019e. Available from: Department of Statistics Malaysia Official Portal (dosm.gov.my)
- International Diabetes Federation. IDF diabetes atlas: 10th edition 2021 [updated 8 Nov 2021]. Available from: https://www.diabetesatlas.org/data/en/country/120/my.html
- Lim S, Lam D-L, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14(1):1–11. doi: 10.1186/s12930-015-0020-9
- Saminathan TA, Hooi LS, Mohd Yusoff MF, et al. Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC Nephrol. 2020;21(1):1–11. doi: 10.1186/s12882-020-01966-8
- Abd Hamid IJ, Azman NA, Gennery AR, et al. Systematic review of primary immunodeficiency diseases in Malaysia: 1979–2020. Front Immunol. 2020;11:1923. doi: 10.3389/fimmu.2020.01923
- Sazlina SG, Sooryanarayana R, Ho BK, et al. Cardiovascular disease risk factors among older people: data from the national health and morbidity survey 2015. PLoS One. 2020;15(10):e0240826. doi: 10.1371/journal.pone.0240826
- Macrotrends. Malaysia smoking rate 2000-2023 2023 [Mar 27, 2023]. Available from: https://www.macrotrends.net/countries/MYS/malaysia/smoking-rate-statistics
- World Health Organization. The global cancer observatory: Malaysia 2021. Available from: https://gco.iarc.fr/today/data/factsheets/populations/458-malaysia-fact-sheets.pdf
- Tartof SY, Slezak JM, Puzniak L, et al. Bnt162b2 vaccine effectiveness against SARS-CoV-2 omicron BA. 4 and BA. 5. Lancet Infect Dis. 2022;22(12):1663–1665. doi: 10.1016/S1473-3099(22)00692-2
- Arbel R, Peretz A, Sergienko R, et al. Effectiveness of the bivalent mRNA vaccine in preventing severe COVID-19 outcomes: an observational cohort study. Available at SSRN 4314067. 2023
- Link-Gelles R. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA. 5–and XBB/XBB. 1.5–related sublineages among immunocompetent adults—increasing community access to testing program, United States, December 2022–January 2023. MMWR Morb Mortal Wkly Rep. 2023;72.
- Surie D, Bonnell L, Adams K, et al. Effectiveness of monovalent mRNA vaccines against COVID-19–associated hospitalization among immunocompetent adults during ba. 1/ba. 2 and ba. 4/ba. 5 predominant periods of sars-cov-2 Omicron variant in the United States—IVY network, 18 States, December 26, 2021–August 31, 2022. Morbidity Mortality Weekly Rep. 2022;71(42):1327–1334. doi: 10.15585/mmwr.mm7142a3
- Surie D. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–Associated hospitalization among immunocompetent adults aged≥ 65 Years—IVY network, 18 states, September 8–November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022;71.
- Ng JW, Chong ETJ, Tan YA, et al. Prevalence of coronavirus disease 2019 (COVID-19) in different clinical stages before the national COVID-19 vaccination programme in Malaysia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(4):2216. doi: 10.3390/ijerph19042216
- Centers for Disease Control and Prevention. Estimated COVID-19 Burden 2022 [updated Aug 12, 2022;January 19, 2023]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/burden.html
- Mattey‐Mora PP, Begle CA, Owusu CK, et al. Hospitalised versus outpatient COVID‐19 patients’ background characteristics and comorbidities: A systematic review and meta‐analysis. Rev Med Virol. 2022;32(3):e2306. doi: 10.1002/rmv.2306
- Sim BLH, Chidambaram SK, Wong XC, et al. Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study. Lancet Reg Health-West Pac. 2020;4:100055. doi: 10.1016/j.lanwpc.2020.100055
- Surendra H, Elyazar IR, Djaafara BA, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Health-West Pac. 2021;9:100108. doi: 10.1016/j.lanwpc.2021.100108
- Menges D, Ballouz T, Anagnostopoulos A, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS One. 2021;16(7):e0254523. doi: 10.1371/journal.pone.0254523
- Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 vaccine booster doses among adults - United States, September 22, 2021-February 6, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18;71(7):249–254.
- Klein NP. Rapid cycle analysis to monitor the safety of COVID-19 vaccines in near real-time within the vaccine safety datalink: myocarditis and anaphylaxis. 2021.
- Ministry of Health Malaysia. COVID-19 detection test charges at international doors and Malaysian ministry of health facilities. Circulated 6 July 2020. Mar2020. Reference (16) KMM.400-9/1/3 Jld Available from: https://mbam.org.my/cost-of-covid-19-testing-charges-at-international-entry-point-and-moh-facility/
- World Health Organization. WHO-CHOICE estimates of cost for inpatient and outpatient health service delivery. 2021 [21 Nov 2022]. Available from: https://www.who.int/teams/health-systems-governance-and-financing/economic-analysis/costing-and-technical-efficiency/quantities-and-unit-prices-(cost-inputs)/econometric-estimation-of-who-choice-country-specific-costs-for-inpatient-and-outpatient-health-service-delivery
- Ministry of Health Malaysia. Pharmaceutical services programme: consumer price guide 2022 [updated 9 Dec 2022;21 November 2022]. Available from: https://www.pharmacy.gov.my/v2/en/apps/drug-price
- Parliament of Malaysia. Second meeting, third term of the fourteenth parliament 2020: answers to oral questions that were not answered in the house (Questions no. 10 to no. 40). 2020.
- Statista Research Department. Labor force participation rate in Malaysia 2021, by age group 2022. Available from: https://www.statista.com/statistics/873483/labor-force-participation-rate-in-malaysia-by-age/
- Saad L, Hickman A Majority of U.S. Workers Continue To Punch In Virtually 2021 [updated 12 Feb 2021]. Available from: https://news.gallup.com/poll/329501/majority-workers-continue-punch-virtually.aspx
- Rahman R Guide to home quarantine for positive COVID-19 patients in Malaysia 2023. Available from: https://www.homage.com.my/resources/home-quarantine-covid-19-positive/
- Centers for Disease Control and Prevention. Ending isolation and precautions for people with COVID-19: interim guidance 2022 [updated 31 Aug 2022]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html
- Thant PW, Htet KT, Win WY, et al. Cost estimates of COVID-19 clinical management in Myanmar. BMC Health Serv Res. 2021;21(1):1–10. doi: 10.1186/s12913-021-07394-0
- Brurberg K, Fretheim A. COVID-19: the relationship between age, comorbidity and disease. mars. 2020;65(1):74.
- Hasani WSR, Ganapathy SS, Lin CZ, et al. Comorbidities and clinical features related to severe outcomes among COVID-19 cases in Selangor, Malaysia. West Pac Surveillance Response J: WPSAR. 2021;12(1):46. doi: 10.5365/wpsar.2020.11.3.007
- W-J G, Z-Y N, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032
- Yang W, Cao Q, Qin L, et al. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): a multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020;80(4):388–393. doi: 10.1016/j.jinf.2020.02.016
- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052–2059. doi: 10.1001/jama.2020.6775
- World Health Organization. Interim statement on booster doses for COVID-19 vaccination 2021 [updated 4 Oct 2021;5 May 2023]. Available from: https://www.who.int/news/item/04-10-2021-interim-statement-on-booster-doses-for-covid-19-vaccination
- Thye A-K, Tan L-H, Law JWF, et al. COVID-19 booster vaccines administration in different countries. Prog Microbes Mol Biol. 2021;4(1). doi: 10.36877/pmmb.a0000256
- Orimo H, Ito H, Suzuki T, et al. Reviewing the definition of “elderly”. Geriatrics & Gerontology Int. 2006;6(3):149–158. doi: 10.1111/j.1447-0594.2006.00341.x
- United Nations Economic and Social Commission for Asia and the Pacific. Social development and ageing societies. Available from: https://www.unescap.org/our-work/social-development/ageing-societies#:~:text=Older%20persons%2C%20defined%20as%20those,be%2060%20years%20or%20over.
- Lochen A, Anderson RM. Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations. Clin Microbiol Infect. 2021 Oct;27(10):1546–1557. doi: 10.1016/j.cmi.2021.07.002
- O’Hare AM, Vig EK, Iwashyna TJ, et al. Complexity and challenges of the clinical diagnosis and management of long COVID. JAMA Netw Open. 2022;5(11):e2240332–e2240332. doi: 10.1001/jamanetworkopen.2022.40332